From the β2-adrenoceptor agonists of the early 1900s to modern-day biologics, asthma treatment has come a long way in improving patients’ lives. The past decade has marked major growth for the latter — a welcome advancement for those living with severe asthma. 

United Nations, AIDS

The global response to AIDS is “under threat” because of an unprecedented backlash against human rights that is stigmatizing the groups most at risk of HIV infection, the head of the United Nations AIDS programme has warned.

Novartis

The company has ramped up its sales growth target as a result of demand for innovative drugs after the spin off of its generics business.

Bayer

Advancing precision health and accelerating access to novel epigenetic and multi-omics at-home biomarker tests to empower consumers on their aging journey.

Novo Nordisk

Novo Nordisk is diverting manufacturing capacity away from its older GLP-1 drug Victoza in order to cater to sky-high Ozempic demand.

While Amgen and Mirati are widely viewed as frontrunners to win the first front line approval, analysts—and competitors—say the field is still wide open.

Today the company said its experimental drug to treat major depressive disorder (MDD) had failed to significantly reduce the severity of the condition in a mid-stage study.

Daiichi Sankyo

The mRNA-based shot was initially approved as a booster in August, becoming Japan’s first home-grown shot for the coronavirus.

GSK logo

GSK said on that its blood cancer drug Blenrep had reached a key goal in a late-stage trial, as the British drugmaker looks to bolster its oncology business after a series of setbacks.

Sanofi

The company plans to seek U.S. approval for its best-selling anti-inflammatory drug Dupixent to be used in the treatment of “smoker’s lung”, also known as COPD, after a second large trial showed significant benefits.